Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Datapharm operates the electronic medicines compendium (emc), a trusted online resource for HCPs and patients, which attracts ...

The recent wave of AI innovation has fallen short of transforming commercial life sciences. In 2025, European biopharmas that ...

"That's a big one," said Trump, as he was handed the WHO order to sign among dozens of others, in a signal of his ...

In his March 2023 budget, the then UK Chancellor, Jeremy Hunt, accordingly announced that from 2024 the Medicines and ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication ...

While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...